Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.50 |
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | GSK3B | P49841 | 5/20 | 0.50 |
| ▸ | CLK2 | P49760 | 5/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 4/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | PIM1 | P11309 | 3/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | ROS1 | P08922 | 2/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145233 | 0.83 | JAK2 (0.49) | ROCK2KDRGSK3BCLK2DYRK1A | |
| SCHEMBL3309445 | 0.81 | JAK2 (0.46) | ROCK2KDRGSK3BCLK2DYRK1A | |
| SCHEMBL3301223 | 0.80 | KDR (0.52) | KDRCDK2PIM1RPS6KB1CSNK2A1 | |
| SCHEMBL3306579 | 0.79 | JAK2 (0.52) | KDRFLT4JAK2FLT1JAK3 | |
| SCHEMBL3304261 | 0.78 | JAK2 (0.48) | KDRFLT4JAK2ABL1EGFR | |
| SCHEMBL3304002 | 0.78 | JAK2 (0.45) | KDRJAK2JAK3PLK1 | |
| SCHEMBL3306759 | 0.77 | JAK2 (0.42) | KDRJAK2JAK3PLK1 | |
| SCHEMBL3306057 | 0.77 | ADORA2A (0.46) | KDRFLT4JAK2FLT1SYK | |
| SCHEMBL3309507 | 0.77 | JAK2 (0.49) | KDRFLT4CDK5CDK5R1JAK2 | |
| SCHEMBL3300054 | 0.75 | JAK2 (0.46) | KDRJAK2PLK4JAK3PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | ROCK2 476/4885KDR 1041/4885GSK3B 852/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | ROCK2 476/4885KDR 1041/4885GSK3B 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.